{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:59:11Z","timestamp":1770825551711,"version":"3.50.1"},"reference-count":76,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,3,13]]},"DOI":"10.18632\/oncotarget.24464","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T08:04:44Z","timestamp":1518163484000},"page":"14922-14938","source":"Crossref","is-referenced-by-count":31,"title":["PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours"],"prefix":"10.18632","volume":"9","author":[{"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Histopathology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Breitwieser","sequence":"additional","affiliation":[{"name":"Molecular Biology Core Facility, Cancer Research UK Manchester Institute, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Ashton","sequence":"additional","affiliation":[{"name":"Manchester Cancer Research Centre (MCRC) BioBank, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Barriuso","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharzad","family":"Moghadam","sequence":"additional","affiliation":[{"name":"Manchester Cancer Research Centre (MCRC) BioBank, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Rogan","sequence":"additional","affiliation":[{"name":"Manchester Cancer Research Centre (MCRC) BioBank, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasat","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Clark","sequence":"additional","affiliation":[{"name":"Molecular Biology Core Facility, Cancer Research UK Manchester Institute, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipasha","family":"Chakrabarty","sequence":"additional","affiliation":[{"name":"Department of Histopathology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Scoazec JY, Couvelard A, and pour le r\u00e9seau TENpath (r\u00e9seau national d\u2019expertise pour le diagnostic anatomopathologique des tumeurs neuroendocrines malignes de l\u2019adulte, sporadiques et familiales). [The new WHO classification of digestive neuroendocrine tumors]. [Article in French]. Ann Pathol. 2011; 31:88-92.","DOI":"10.1016\/j.annpat.2011.01.001"},{"key":"3","first-page":"13","volume-title":"WHO classification of tumors of the digestive system","author":"Hruban","year":"2010"},{"key":"4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Martinez","year":"2014","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Arnold","year":"2009","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Baum","year":"2017","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Sachs","year":"2016","journal-title":"Lancet"},{"key":"8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","article-title":"Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?","volume":"44","author":"Valle","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"10","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Neyns","year":"2015","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"O\u2019Day","year":"2015","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Zarour","year":"2014","journal-title":"Lancet"},{"key":"13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Antonia","year":"2012","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Selby","year":"2010","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Hotta","year":"2016","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Felip","year":"2015","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"de Castro","year":"2016","journal-title":"Lancet"},{"key":"18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Chow","year":"2016","journal-title":"Lancet Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Muro","year":"2016","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","volume":"374","author":"Kohrt","year":"2016","journal-title":"N Engl J Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Daud","year":"2015","journal-title":"Clin Cancer Res"},{"key":"22","unstructured":"Merck: Pembrolizumab (Keytruda) Merck product information. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf."},{"key":"23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS Consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Krenning","year":"2016","journal-title":"Neuroendocrinology"},{"key":"24","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdx368","article-title":"Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"28","author":"Le Tourneau","year":"2017","journal-title":"Ann Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Ahr\u00e9n","year":"2003","journal-title":"Br J Surg"},{"key":"26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Alm","year":"1983","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0016-5085(00)70143-0","article-title":"Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells","volume":"118","author":"Rosewicz","year":"2000","journal-title":"Gastroenterology"},{"key":"28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors\u2014the International Lanreotide and Interferon Alfa Study Group","volume":"21","author":"Wiedenmann","year":"2003","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1479-5876-9-196","article-title":"Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application","volume":"9","author":"Ribas","year":"2011","journal-title":"J Transl Med"},{"key":"30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.hoc.2014.02.002","article-title":"Immune checkpoint blockade","volume":"28","author":"Wolchok","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Chen","year":"2002","journal-title":"Nat Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Minato","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal","volume":"10","author":"Bluestone","year":"2009","journal-title":"Nat Immunol"},{"key":"34","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"key":"35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Buettner","year":"2015","journal-title":"Eur J Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7150\/jca.13711","article-title":"The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs","volume":"7","author":"Park","year":"2016","journal-title":"J Cancer"},{"key":"37","article-title":"Immune checkpoint markers and immune response in well differentiated neuroendocrine tumors (NET) of the small intestine and pancreas","author":"Kulke","year":"2016","journal-title":"NANETS Symposium"},{"key":"38","article-title":"PD1 and PDL1 Expression in Midgut Neuroendocrine Tumors","author":"Coppola","year":"2016","journal-title":"13th Annual ENETS conference"},{"key":"39","first-page":"7610","article-title":"Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas","volume":"7","author":"Schmieder","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"40","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/OTT.S115054","article-title":"Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors","volume":"9","author":"Wu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"41","article-title":"The positive expression of PD-L1\/PD-1 in gastroenteropancreatic neuroendocrine neoplasias correlated with prognosis","author":"Chuying","year":"2017","journal-title":"14th Annual ENETS conference"},{"key":"42","article-title":"Analysis of mTOR, CXCR4 and PD-1 checkpoint pathways in merkel cell neuroendocrine carcinomad: correlations with prognosis and viral status","author":"Maubec","year":"2017","journal-title":"14th Annual ENETS conference"},{"key":"43","article-title":"PD-L1 is expressed in a subset of pancreatic neuroendocrine tumours (pNET)","author":"Perren","year":"2017","journal-title":"14th Annual ENETS conference"},{"key":"44","article-title":"PD-L1 expression and quantitative assessment of tumor-infiltrating T cell subsets in carcinoid tumors and large cell neuroendocrine carcinomas of the lung","author":"Adam","year":"2017","journal-title":"14th Annual ENETS conference"},{"key":"45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.humpath.2016.02.002","article-title":"A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma","volume":"52","author":"Cerroni","year":"2016","journal-title":"Hum Pathol"},{"key":"46","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Lorch","year":"2016","journal-title":"Lancet Oncol"},{"key":"47","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.5301\/jbm.5000225","article-title":"Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis","volume":"32","author":"Kim","year":"2017","journal-title":"Int J Biol Markers"},{"key":"48","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"de Jong","year":"2016","journal-title":"J Clin Oncol"},{"key":"49","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1477-2574.2010.00231.x","article-title":"T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases","volume":"12","author":"Tang","year":"2010","journal-title":"HPB"},{"key":"50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Ohe","year":"2016","journal-title":"Lung Cancer"},{"key":"51","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","article-title":"PD-1 Blockers","volume":"162","author":"Wolchok","year":"2015","journal-title":"Cell"},{"key":"52","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Wolchok","year":"2015","journal-title":"J Clin Oncol"},{"key":"53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","article-title":"Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy","volume":"9","author":"Li","year":"2016","journal-title":"J Hematol Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition","volume":"22","author":"Evers","year":"2016","journal-title":"Clin Cancer Res"},{"key":"55","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1158\/1078-0432.CCR-14-0933","article-title":"The future of cancer therapy: selecting patients likely to respond to PD1\/L1 blockade","volume":"20","author":"Tumeh","year":"2014","journal-title":"Clin Cancer Res"},{"key":"56","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/JCO.2017.35.15_suppl.4013","article-title":"Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study","volume":"35","author":"Yeo","year":"2017","journal-title":"J Clin Oncol"},{"key":"57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Butler","year":"2013","journal-title":"Nature"},{"key":"58","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/annonc\/mdu227","article-title":"Immunoscoring breast cancer: TILs remember what they target","volume":"25","author":"Perez","year":"2014","journal-title":"Ann Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Denkert","year":"2014","journal-title":"Ann Oncol"},{"key":"60","first-page":"355","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Elledge","year":"2017","journal-title":"Science"},{"key":"61","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/modpathol.2009.80","article-title":"Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations","volume":"22","author":"Latouche","year":"2009","journal-title":"Mod Pathol"},{"key":"62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Hudgens","year":"2018","journal-title":"Science"},{"key":"63","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Felip","year":"2015","journal-title":"PLoS One"},{"key":"64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1158\/1078-0432.CCR-15-0715","article-title":"PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma","volume":"22","author":"Ting","year":"2016","journal-title":"Clin Cancer Res"},{"key":"65","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1158\/2326-6066.CIR-16-0110","article-title":"Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups","volume":"4","author":"Choueiri","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"66","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Zaheer","year":"2015","journal-title":"N Engl J Med"},{"key":"67","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","author":"Philips","year":"2013","journal-title":"Nat Genet"},{"key":"68","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1172\/JCI67963","article-title":"The genomic landscape of small intestine neuroendocrine tumors","volume":"123","author":"Wu","year":"2013","journal-title":"J Clin Invest"},{"key":"69","article-title":"Mismatch repair (MMR) protein expression is uncommon in poorly differentiated neuroendocrine carcinoma","author":"Scoazec","year":"2017","journal-title":"14th Annual ENETS conference"},{"key":"70","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-cell Infiltration and PD-L1","volume":"75","author":"Smyth","year":"2015","journal-title":"Cancer Res"},{"key":"71","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00262-014-1521-3","article-title":"Monitoring the immune competence of cancer patients to predict outcome","volume":"63","author":"Maecker","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"72","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.ejca.2013.02.035","article-title":"Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers","volume":"49","author":"Linnebacher","year":"2013","journal-title":"Eur J Cancer"},{"key":"73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/labinvest.2014.157","article-title":"Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic","volume":"95","author":"Rimm","year":"2015","journal-title":"Lab Invest"},{"key":"74","unstructured":"Adult Comorbidity Evaluation-27 http:\/\/www.rtog.org\/LinkClick.aspx?fileticket=oClaTCMufRA%3D&tabid=290."},{"key":"75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"76","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Anders","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T23:52:40Z","timestamp":1603842760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":76,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2018,3,13]]}},"alternative-id":["24464","29599916"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24464","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]}}}